Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer

Journal of Clinical Investigation

Volumn 115, Issue 4, 2005, Pages 978-985

  Nogawa, Masaki ^a,e   Yuasa, Takeshi ^a   Kimura, Shinya ^a   Tanaka, Motoyoshi ^b   Kuroda, Junya ^a   Sato, Kiyoshi ^a   Yokota, Asumi ^a   Segawa, Hidekazu ^a   Toda, Yoshinobu ^c   Kageyama, Susumu ^d   Yoshiki, Tatsuhiro ^d   Okada, Yusaku ^d   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B1; POLO LIKE KINASE 1; POLO LIKE KINASE 1 SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MITOSIS SPINDLE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE;

EID: 20144387142     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23043     Document Type: Article

References (32)

1. Messing, E.M. 2001. Urothelial tumors of the urinary tract. In Campbell's urology. P.C. Walsh, A.B. Retik, E.D. Vaughan Jr., and A.J. Wein, editors. W.B. Saunders Co. New York, New York, USA. 2732-2784.
2. Gee, J., Sabichi, A.L., and Grossman, H.B. 2002. Chemoprevention of superficial bladder cancer. Crit. Rev. Oncol. Hematol. 43:277-286.
3. Cookson, M.S., et al. 1997. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 158:62-67.
4. Lieberman, J., Song, E., Lee, S.K., and Shankar, P. 2003. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol. Med. 9:397-403.
5. Dorsett, Y., and Tuschl, T. 2004. siRNAs: applications in functional genomics and potential as therapeutics. Nat. Rev. Drug Discov. 3:318-329.
6. Barr, F.A., Sillje, H.H., and Nigg, E.A. 2004. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 5:429-440.
7. Holtrich, U., et al. 1994. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc. Natl. Acad. Sci. U. S. A. 91:1736-1740.
8. Wolf, G., et al. 1997. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene. 14:543-549.
9. Strebhardt, K., Kneisel, L., Linhart, C., Bernd, A., and Kaufmann, R. 2000. Prognostic value of polo-like kinase expression in melanomas. JAMA. 283:479-480.
10. Knecht, R., et al. 1999. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59:2794-2797.
11. Spankuch-Schmitt, B., Bereiter-Hahn J., Kaufmann, M., and Strebhardt, K. 2002. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 94:1863-1877.
12. Liu, X., and Erikson, R.L. 2003. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100:5789-5794.
13. Hirabayashi, K., et al. 1999. Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res. 59:4325-4333.
14. Sledz, C.A., Holko, M., de Veer, M.J., Silverman, R.H., and Williams, B.R. 2003. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5:834-849.
15. Brummelkamp, T.R., Bernards, R., and Agami, R. 2002. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:243-247.
16. Song, E., et al. 2003. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9:347-351.
17. Spankuch, B., et al. 2004. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J. Natl. Cancer Inst. 96:862-872.
18. Sioud, M., and Sorensen, D.R. 2003. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312:1220-1225.
19. Sorensen, D.R., Leirdal, M., and Sioud, M. 2003. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327:761-766.
20. Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A., and Herweijer, H. 2002. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32:107-108.
21. Zender, L, et al. 2003. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. U. S. A. 100:7797-7802.
22. Hacein-Bey-Abina, S., et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346:1185-1193.
23. McCormack, M.P., and Rabbitts, T.H. 2004. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350:913-922.
24. Hacein-Bey-Abina, S., et al. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:255-256.
25. Marwick, C. 1998, First "antisense" drug will treat CMV retinitis. JAMA 280:871.
26. Kageyama, S. 2002. High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn. J. Cancer Res. 93:523-531.
27. Kimura, S., Maekawa, T., Hirakawa, K., Murakami, A., and Abe, T. 1995. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res. 55:1379-1384.
28. Kuroda, J., et al. 2003. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood. 102:2229-2235.
29. Knecht, R., Oberhauser, C., and Strebhardt, K. 2000. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int. J. Cancer. 89:535-536.
30. Luo, J.L., Maeda, S., Hsu, L.C., Yagita, H., and Karin, M. 2004. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 6:297-305.
31. Nogawa, M., et al. 2005. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett. 217:243-253.
32. Tanaka, M., et al. 2003. Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J. Urol. 170:975-978.